Immunomagnetic Nanoprobe-Mediated Capture of Circulating Multiple Myeloma Cells for Monitoring of Proteasome Inhibitor Response

- MIL_ 88 B @CD138/CD38 nanoprobe and systematically evaluated the correlations between CMMC counts and key clinicopathologic parameters and clinical therapeutic response to PIs in MM patients. CMMC counts were associated with MM clinical stages. Moreover, dynamic changes in CMMC counts measured by this nanoprobe can sensitively reflect responses to PIs therapy. Specifically, CMMC counts were elevated in nearly all patients with progressive disease and decreased in patients with a favorable treatment response. This work provides a potential index for real-time assessing MM disease progression and PIs treatment outcomes.